1. Home
  2. ASAN vs PHVS Comparison

ASAN vs PHVS Comparison

Compare ASAN & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Asana Inc.

ASAN

Asana Inc.

N/A

Current Price

$8.98

Market Cap

2.1B

Sector

Technology

ML Signal

N/A

Logo Pharvaris N.V.

PHVS

Pharvaris N.V.

N/A

Current Price

$31.63

Market Cap

2.4B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ASAN
PHVS
Founded
2008
2015
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Retail: Computer Software & Peripheral Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
2.4B
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
ASAN
PHVS
Price
$8.98
$31.63
Analyst Decision
Hold
Strong Buy
Analyst Count
15
14
Target Price
$10.23
★ $58.27
AVG Volume (30 Days)
★ 4.1M
465.2K
Earning Date
12-01-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 27.93
N/A
EPS
N/A
★ N/A
Revenue
★ $790,806,000.00
N/A
Revenue This Year
$8.95
N/A
Revenue Next Year
$7.86
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 9.25
N/A
52 Week Low
$5.38
$23.15
52 Week High
$15.28
$43.25

Technical Indicators

Market Signals
Indicator
ASAN
PHVS
Relative Strength Index (RSI) 35.56 42.13
Support Level $8.86 $28.16
Resistance Level $9.34 $36.14
Average True Range (ATR) 0.55 1.63
MACD -0.25 -0.24
Stochastic Oscillator 1.36 7.65

Price Performance

Historical Comparison
ASAN
PHVS

About ASAN Asana Inc.

Asana Inc is the system of action for work, built for the Agentic Enterprise. It provides a comprehensive solution where humans and AI agents can collaborate effectively so that individuals work smarter, teams move faster, and organizations deliver results. Companies use Asana to connect their work to company goals and orchestrate mission-critical workflows like product launches, employee onboarding, resource planning, tracking company-wide strategic initiatives and more. It manages its operations and allocates resources as a single operating and reportable segment. The company generates revenues from subscriptions from paying customers accessing its cloud-based platform.

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.

Share on Social Networks: